Oncology Other denied for failing step therapy by Blue Cross Blue Shield?

For Anthem Blue Cross Blue Shield Marketplace (Individual & Commercial) members, oncology drugs administered under the medical benefit are delegated to Carelon Medical Benefits Management (formerly AIM Specialty Health) for prior authorization review. Carelon uses an evidence- and value-based approach utilizing cancer treatment pathways, provider-preferred clinical review, and enhanced reimbursement and pathway adherence reporting, covering approximately 85% of spending on cancer drugs across therapeutic and supportive drugs. Carelon Cancer Treatment Pathways are cancer treatment regimens intended to support quality cancer care and reduce unneeded variation in care and cost, developed through a rigorous process of integrating evidence-based literature with physician practice guidelines. Pathways identify a subset of regimens supported by clinical evidence and practice guidelines, selected based on clinical benefit (efficacy), safety/side effects (especially those leading to hospitalizations and impacting quality of life), strength of national guideline recommendations, and cost of regimens. Off-pathway requests are reviewed individually: the platform approves requests that align with policy and pathways, and board-certified medical oncologists and nurses consult on off-pathway requests and alert providers to enhanced reimbursement opportunities. For some health plans, requested services are reviewed in accordance with client medical policies and clinical guidelines; if a request is received that is not a Carelon Pathway regimen, it may be reviewed and authorized if determined to be medically necessary, with reference to NCCN Clinical Practice Guidelines in Oncology. Critical elements include confirming the diagnosis based on a complete evaluation including history, physical examination, relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention, with anticipated benefit outweighing potential harms. Self-administered/oral oncology drugs under the pharmacy benefit are reviewed against CarelonRx clinical criteria approved by the CarelonRx Pharmacy and Therapeutics Committee, an independent external committee of practicing physicians, pharmacists, and clinicians from leading academic medical centers with expertise in evidence-based medicine across all major clinical specialties.

- Carelon's own framework permits off-pathway approval when medically necessary: the treating oncologist determines if a Pathway regimen is the best option or whether, given the patient's unique circumstances, another regimen is a better choice, and non-Pathway requests may be authorized if determined to be medically necessary, referencing NCCN Clinical Practice Guidelines in Oncology. - Cite the specific NCCN Clinical Practice Guideline (Category 1 or 2A recommendation) supporting the requested regimen for the patient's histology, stage, and biomarker status — Carelon explicitly references NCCN as an authoritative source for medical necessity determinations. - Submit biomarker/pathology reports (e.g., NGS, IHC, FISH) confirming the targetable alteration required by the FDA label or NCCN guideline; Carelon requires confirmation of the diagnosis based on complete evaluation including review of relevant laboratory studies and diagnostic testing. - For step-therapy denials, document contraindication, intolerance, or prior failure of preferred agents; step therapy requires that the member has tried an alternative therapy first, or that the prescriber has clinically documented why the member cannot take the alternative therapy. - Demonstrate that benefit outweighs harm and delay would worsen outcomes: the anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to treatment. - Invoke clinician authority and individualization: medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition, and the treating clinician has final authority and responsibility for treatment decisions and for justifying medical necessity. - For Marketplace ACA plans, cite the ACA's essential health benefit protections and the plan's obligation to follow recognized compendia (NCCN Drugs & Biologics Compendium, AHFS, Micromedex DrugDex) for off-label oncology indications, which Carelon's pathway framework already incorporates via NCCN alignment.

## Why BCBS Applies Step Therapy to Oncology Drugs — and Why It Is Frequently Overturned

Step-therapy (also called "fail-first") requirements ask patients to try one or more preferred medications before the plan will authorize the prescribed therapy. In oncology, applying step therapy is clinically problematic and legally vulnerable: cancer treatment is protocol-specific, time-sensitive, and guided by tumor histology, molecular markers, and prior-treatment history in ways that a generic step-therapy ladder cannot anticipate. Most state-level step-therapy reform laws and federal guidance specifically recognize that step therapy is inappropriate when it would delay care for a serious or life-threatening condition.

## Your Federal Appeal Rights

ACA §2719 and ERISA §503 guarantee an internal appeal followed by binding external review by an Independent Review Organization (IRO). The external-review window is generally available within approximately four months of the initial denial. If delay poses a serious health risk, request an expedited appeal — plans must typically adjudicate expedited internal appeals within 72 hours and expedited external reviews within 72 hours of a valid request.

## Concrete Appeal Steps

1. Obtain the denial letter and the step-therapy protocol — confirm which drugs BCBS requires you to try first, and whether any exemption criteria exist. 2. Check your state's step-therapy law — many states (and federal rules for fully-insured plans) require automatic exemptions when the required step drug is contraindicated, when the patient has already tried it, or when delay would adversely affect health. 3. File the internal appeal — include your oncologist's letter, relevant guideline references, and the criteria-mapping table described below. 4. Request external review — if the internal denial is upheld, escalate to binding IRO review.

## Documentation to Gather

• Diagnosis and molecular/biomarker profile: pathology and genomic reports supporting why the prescribed agent is the guideline-concordant choice for this specific tumor type and molecular context.
• Prior treatment history: dates, agents, doses, and outcomes of any prior lines of therapy, demonstrating which step-therapy options have already been tried and failed or are clinically inappropriate.
• Oncologist's medical-necessity letter: a statement that the required step-therapy drugs are clinically unsuitable for this patient and that delay poses a serious health risk, with reference to the applicable NCCN or other recognized oncology guideline.
• FDA-approved prescribing information: confirmation of the indication and that the prescribed use falls within it.
• Urgency documentation: imaging, performance-status notes, or lab trends supporting expedited review if applicable.

## Criteria-Mapping Structure

Retrieve the exact step-therapy exemption criteria from the BCBS published policy and any applicable state step-therapy law. Create a table with each exemption criterion in the left column and the specific chart evidence satisfying it in the right column. Pay particular attention to the exemption for patients who have already tried the required prior step — prior-treatment records with clear outcome documentation are the most persuasive evidence in step-therapy appeals for oncology.